

## CURRICULUM VITAE

January 2005

**Name:** Om P. Ganda, M.D.; FACE

**Address:** Joslin Diabetes Center, One Joslin Place, Boston, MA 02215  
Tel: (617) 732-2675 (Office); (781) 431-1139 (Home)

**Place of Birth:** W. Punjab, India (citizenship-U.S.A.)

### Education:

1961 Raj Rishi College, Alwar, Rajasthan, India (Pre-Med)  
1966 S.M.S. Medical College, University of Rajasthan, Jaipur, India (M.B.B.S.)

### Postdoctoral Training:

4/66-11/66 Rotating Internship, S.M.S. Hospital, Jaipur, Rajasthan, India  
1/67-6/67 House Officer in Medicine, All India Institute of Medical Sciences Hospital, New Delhi, India  
7/67-12/67 House Officer in Cardio-Thoracic Surgery, All India Institute of Medical Sciences, New Delhi, India  
1968-70 Resident in Medicine, All India Institute of Medical Sciences, New Delhi, India  
1971 Registrar in Medicine, All India Institute of Medical Sciences, New Delhi, India  
1971-72 Resident in Medicine, Lemuel Shattuck Hospital and Tufts University School of Medicine, Boston, MA

### Fellowships:

1972-73 Clinical Fellow in Endocrinology and Metabolism, Boston Veterans Administration Hospital and Tufts University School of Medicine, Boston, MA  
1973-76 Research Fellow in Medicine, Harvard Medical School  
1973-76 Research Fellow in Medicine, E.P. Joslin Research Laboratory at the Peter Bent Brigham Hospital, Boston, MA

### Licensure and Certification:

1970 Doctorate in Internal Med. (M.D.), All India Institute of Medical Sciences, New Delhi, India  
1973 Diplomate of American Board of Internal Medicine  
1973 Massachusetts Licensure in Medicine #35771 (June 1973)  
1974 Fellow of Royal College of Physicians and Surgeons and Canada (FRCP -C )  
1975 Diplomate of the American Board of Endocrinology and Metabolism  
1981 American Board of Nutrition-Specialist in Clinical Nutrition

Ganda, Om P.

**Academic Appointments:**

1976-78 Instructor in Medicine, Harvard Medical School, Boston, MA  
1979-91 Assistant Professor of Medicine, Harvard Medical School,  
Boston, MA  
1991- Associate Clinical Professor of Medicine, Harvard Medical School,  
Boston, MA

**Hospital Appointments:**

1976-82 Junior Associate in Medicine, Brigham and Women's Hospital,  
Boston, MA  
1977- Physician, Joslin Clinic, Joslin Diabetes Center, Boston, MA  
1977- Staff Physician in Medicine, Beth Israel Deaconess Medical Center, West  
Campus (formerly New England Deaconess Hospital),  
Boston, MA  
1982- Associate Physician, Brigham and Women's Hospital, Boston, MA

**Other Professional Positions:**

1976- Investigator, E.P. Joslin Research Laboratory, Joslin  
Diabetes Center, Boston, MA

**Principal Clinical and Hospital Service Responsibilities:**

1977- Attending Physician, General Medical Service, Beth Israel Deaconess  
Medical Center (formerly New England Deaconess Hospital), Boston,  
MA.  
1977- Attending Physician, Diabetes Treatment Unit, Beth Israel Deaconess  
Medical Center (formerly New England Deaconess Hospital), Boston, MA.  
1980- Consulting Physician, Endocrine Consult Service, Beth Israel Deaconess  
Medical Center (formerly New England Deaconess Hospital), Boston, MA  
1985- Examiner, American Board of Internal Medicine at the New England  
Deaconess Hospital, Boston, MA.  
1986- Director, Lipid Clinic, Joslin Diabetes Center, Boston, MA.

**Administrative Responsibilities:**

1980-84 Coordinator, Endocrine Consult Service, New England Deaconess  
Hospital and Endocrine Clinic, Joslin Diabetes Center, Boston, MA.  
1982-84 Coordinator, Clinical Research Section, Joslin Diabetes Center,  
Boston, MA.  
1986-87 Co-Director, Clinical Research Center Core, Joslin Diabetes and  
Endocrinology Research Center (DK# 36381).  
1992-96 Board of Governors, Joslin Diabetes Center.  
1998- Co-Director, Clinical Diabetes and Metabolism Conference, Joslin  
Diabetes Center and Beth Israel Deaconess Medical Center.

Ganda, Om P.

**Major Committee Assignments:**

1978-85	Committee on Clinical Investigation, New England Deaconess Hospital, Boston, MA
1979-82	Research Committee, Joslin Diabetes Center, Boston, MA (Chairman)
1983-92	Committee on Staff Membership, New England Deaconess Hospital,
1986-93	Standards and Methods Committee, Diabetes Control and Complications Trial (DCCT), National Institutes of Health
1994-95	Search Committee for Professional Personnel, Joslin Diabetes Center, (Chairman)
1995-98	Finance Committee, Joslin Diabetes Center
1998-2000	Steering Committee, Council on Complications, American Diabetes Association (ADA).
1982-	Fellowship Committee, Joslin Diabetes Center
1998 -	Lipid Disorders Task Force, American Association of Clinical Endocrinologists (AACE)
2001-	Member, Joslin Clinic Oversight Committee
2001-	Member, Takeda Diabetes Advisory Board
2002-	Steering Committee, National Diabetes Education Program (NDEP)
2002-	Member, National Diabetes/Lipid Advisory Board (Merck)
2003-	Moderator, New England Endocrinology Consultancy Initiative (Pfizer)

**Professional Societies:**

1974	American Diabetes Association (ADA)	Member
1975	Endocrine Society	Member
1998	American Association of Clinical Endocrinology	Board of Directors
	2000-2003 (AACE)	

**Community Service:**

1979-	Numerous lectures at the meetings of the Indian Medical Association of New England (IMANE).
1980-	Various lectures and workshops at the American Diabetes Association (ADA) - Massachusetts affiliate.
2000 -	Life member, American Association of Physicians of Indian Origin (AAPI) – various activities and lectures.
2000-3	Member, Board of Governors, American Association of Clinical Endocrinologists (AACE)

**Editorial Experience:**

1978-85	Technical Reviewer, New England Journal of Medicine
1976-	Manuscript reviewer on a periodic basis for various journals including Diabetes, Diabetes Care, Diabetologia, J. Clin Endocrinol Metab, JAMA, New England Journal of Medicine, etc.
1993	Abstracts reviewer, ADA Annual Meeting Scientific Sessions
1988-	Editorial Board, Diabetes Research and Clinical Practice

Ganda, Om P.

**Awards and Honors:**

1966	S.M.S. Gold Medal for securing first place, in order of merit, in the final M.B.B.S. Exam at Univ. of Rajasthan, India
1966	Pfizer Gold Medal in Internal Medicine for securing highest marks in Internal Medicine in the final M.B.B.S. exam
1972	Prize for “Best Performance of Junior Resident” for the year 1971-1972 at Lemuel Shattuck Hospital, Boston, MA
1975	Marios Balodimos Award at the Annual Scientific Session of the New England Diabetes Association
1977	“Capps Scholar” Award, Harvard Medical School, Boston, MA
1987	“Outstanding Teacher” Award by Joslin Clinic Fellows
1995	RV Sathe Golden Jubilee Oration, Diabetes Association of India.
2000	GP Moses Oration, Research Society for the Study of Diabetes in India
2003	M.Viswanathan Oration, Research Society for the Study of Diabetes in India

**Report of Clinical Practice and Teaching**

A. Narrative Report

Clinical practice: Primarily in the field of endocrinology, diabetes and metabolism, based in the academic setting of the Joslin Diabetes Center and the Beth Israel Deaconess Medical Center, a major teaching hospital of the Harvard Medical School. The main focus of practice is in the area of adult diabetes and its complications as well as lipid disorders. Other related areas include islet cell tumors and disorders of hypoglycemia.

Time commitments: Approximate time commitments vary according to clinical research funding but are broadly distributed as follows:

Direct patient care	55-60 %
Clinical Research	20-25 %
Teaching	15-20 %
Administrative	2.5 – 5 %

**Patient load, Complexity**

A large number of patients, including 5-10 new patients and 30-40 follow-up visits weekly. Most patients are highly complicated referrals from other physicians or health care sources. The nature of complexities include type 1 and type 2 diabetes with difficulties in glycemic control despite complicated insulin regimens; cardio-vascular and peripheral vascular disease; severe, recurrent hypoglycemia; and progressive microvascular or neuropathic disease.

**Clinical program development:**

Special interest in lipid disorders and atherosclerosis. Participation in clinical trials relating to lipid-lowering drugs and diabetes management.

B. Scholarly Contributions

**1. Current Research Projects**

- i) Long-term efficacy and safety study with a novel protein kinase C inhibitor, LY333531, in diabetic retinopathy.

- ii) Lipid lowering drug trials.

**Past:**

July '74 – June '76	#AM 05301 U.S.P.H.S. Fellowship Award
July '76 - Nov '83	#AM 09748 Co-Principal investigator Title: Diabetes-Detection, Pathogenesis and Oral Agents
July '77 - June '79	Capps Scholar in Diabetes Awarded by Harvard Medical School
April '78 - Sept '81	#AM 20530 Director: Lipid Core Title: Diabetes Research and Training Center (DRTC)
April '84 - Dec '87	#AM 33790 Co-Investigator Title: Pathogenesis of Type I Diabetes in Monozygotic Twins
Nov '86 - Aug '88	DK# 36381 Director - Clinical Research Center Core Title: Joslin Diabetes Endocrinology Center (Joslin DERC)
April '88 - April '90	Squibb Pharmaceuticals, Inc. Principal Investigator Title: Effect of Pravastatin in Hypercholesterolemia Associated with Diabetes
Feb '90 - Feb '93	Pfizer Pharmaceuticals, Inc. Principal Investigator Title: Effect of Glipizide in Prevention of Non-insulin Dependent Diabetes

Ganda, Om P.

April '86 - June '93	DK# 30633 Co-Investigator Title: Diabetes Control and Complications Trial (DCCT)
Oct '92 - Sept '94	Hoechst-Roussel Pharmaceuticals, Inc. Principal Investigator Title: Efficacy and Safety of HOE 490 vs Glipizide in patients with Non-insulin Dependent Diabetes
July '93 - June '94	Diabetes Research and Education Foundation (DREF) #C29/I-93 Principal Investigator Title: Susceptibility of plasma lipoprotein lipids to Peroxidation in diabetes
Sept '97 - July '98	Hoechst-Roussel Pharmaceuticals, Inc. Principal Investigator (HOE 3004, HOE 3006) Title: Long-acting insulin analog (HOE901) in type 1 and type 2 diabetes
Jan '98 - Dec '98	Merck Pharmaceuticals (MK733/143-00) Principal Investigator comparative efficacy of simvastatin and atorvastatin in type 2 diabetes and hypercholesterolemia
Sept '98-Dec '99	KOS Pharmaceuticals (Protocol MA-98-0108) Principal Investigator Title: A randomized, double-blind, placebo, controlled study of the safety and efficacy of Niaspan (extended release niacin) in type 2 diabetic patients with dyslipidemia.
Sept '98 – March '00	Park-Davis Pharmaceutical Research Co-Investigator (Protocol 991-128) Title: Study of Troglitazone in early type 2 diabetes mellitus; effects on glucose metabolism, insulin sensitivities, and $\beta$ -cell response to glucose
July '96- June '03	DK# 48437 Co-investigator Title: Diabetes Prevention Program (DPP); N.I.H.

Ganda, Om P.

<b><u>Current:</u></b>	July '93 -	DK# 30633-11 Co-investigator Title: Epidemiology of Diabetes Intervention and Complications (EDIC) ; N.I.H
	Sept '98-	Eli Lilly Research Laboratories (Protocol B7A-MC-MBBK and B7A-MC-MBBM) Co-Investigator, Title: Role of protein-kinase C inhibitor, LY333531 in diabetic retinopathy and diabetic macular edema
	May '02- June '04	Kos Pharmaceuticals (Protocol MA-01-010402) Co-Investigator Title: Advicor in Diabetes and Dyslipidemia
	May '03-	DK# 60115-02 Co-Investigator Title: Breaking Down Barriers to Diabetes Self-care

## C. Teaching Contributions:

## 1. Local Contributions:

1972-73	Teaching Fellow, Tufts University School of Medicine at Boston Veterans Administration Hospital, Boston, MA.
1972-74	Instructor, Endocrine Course Curriculum for 2 <sup>nd</sup> -year medical students at Tufts University School of Medicine, Boston, MA.
1975-76	Instructor, Physical diagnosis for 3 <sup>rd</sup> year medical students, Boston University School of Medicine, Boston, MA.
1986-91	Lecturer, Endocrine-Pathophysiology course for 2 <sup>nd</sup> year medical students at Tufts University School of Medicine.
1976-96	Attending, Endocrine-metabolism section, Brigham and Women's Hospital, Boston, MA.
1976-	Lecturer, Endocrine-metabolism lecture series, New England Deaconess Hospital and Joslin Diabetes Center, Boston, MA.
1976-	Faculty Member, Annual Harvard-Joslin Course on Diabetes for practicing physicians, Boston, MA.
1976-	Invited Lecturer, numerous medical centers in and outside the Boston area. (Approximately 20-30 lectures per year)
1985-	Evaluator, HMS II Introduction to Clinical Medicine Course
1996-	Tutor, HMS III Ambulatory subspecialty rotation.

Ganda, Om P.

## 2. Other Selected National and International Contributions:

- 1976-present Over 1,000 grand-rounds and lectures at various medical centers in U.S. and Canada.
- 1979: Invited speaker at Postgraduate Course on Diabetes in Budapest, Hungary (Sept. 17-20); a satellite symposium to the 10<sup>th</sup> Congress of the International Diabetes Federation in Vienna. Topic: Facing the Facts About Hyperlipidemia.
- 1982: Invited speaker at W.H.O. Postgraduate Course on Diabetes during “Diabetes week in Yugoslavia” in Opatija, Yugoslavia, (March 21-27); Multiple lectures and workshops.
- 1987: Diabetes Diagnostic Strategy Computer Program - an interactive case problem-solving video program displayed at the 47<sup>th</sup> American Diabetes Association Annual meeting, Indianapolis, Indiana, June 6-9 (developed 6 of 24 clinical cases for use by medical professionals). Sponsored by Health Sciences Medical Inc., Atlanta, Georgia.
- 1988: Panel member at Simvastatin Consultants meeting, Woodbridge, N.J., May 25; coordinated by Merck, Sharpe & Dohme Research Laboratories, Rahway, N.J. (Dr. George Steiner, - Moderator).
- 1989: Chairman, “Management of Type II Diabetes, Challenges in the 1990’s”, a symposium at the Marriott Hotel, Newton, MA, Oct. 18; sponsored by American Diabetes Association and the Hoechst - Roussel Pharmaceuticals, Inc., Somerville, N.J.
- 1989: Invited speaker at National University of Singapore, Singapore, Dec. 24. (Diabetes Pathogenesis)
- 1989: Invited speaker at Queen Mary Hospital, University of Hong Kong, Dec. 29. (Current status of Diabetes Control and Complications Trial).
- 1990: Moderator, “High-Density Lipoprotein and Coronary Heart Disease”, a symposium at Hyatt Regency Hotel, Cambridge, MA, May 24, Sponsored by the Postgraduate Medical Institute and the Park-Davis, Inc., N.J.
- 1990: Plenary lectures and Meet-the-Professor sessions at Indo - U.S. Symposium and Workshops on Endocrinology, Metabolism and Diabetes, New Delhi, India, Dec. 26-31; cosponsored by All India Institute of Medical Sciences and the Fogarty International Center, Bethesda, Maryland.
- 1991: Invited speaker at the 19<sup>th</sup> Annual Diabetes Symposium on current topics in Diabetes and Vascular Disease, Dec. 13-14; Kilo Diabetes and Research Foundation and Washington Univ. School of Medicine, St. Louis, Mo. (“Mechanisms and Management of Hypertension in Diabetes:”).
- 1992: Participant, International Symposium on Fibrinogen - a cardiovascular risk factor, University of Vienna, Austria, Jan. 27-28 (Prof E. Ernst, Symposium chairman).
- 1993: Invited speaker at Neuropathy Circles Project '93 under the auspices of Juvenile Diabetes Foundation, Joslin Diabetes Center, and Gruppo di Studio sulla Neuropatica Diabetica. Puerto-Vallarta, Mexico, Nov. 12-13 (2 Lectures).

Ganda, Om P.

- 1993: Plenary lectures and meet-the-professor sessions at the 2<sup>nd</sup> Indo-U.S. Symposium and Workshops on Endocrinology, Metabolism and Diabetes Bombay, India, Dec. 27-29.
- 1994: Visiting Professor, Northeastern Ohio Universities College of Medicine and Affiliated Hospitals at Canton, Ohio, Sept. 15 (Lecture and case discussions).
- 1994: Invited speaker at the Harvard Medical School course on “Contemporary issues in Nephrology” at Copley Plaza Hotel, Boston, Sept. 26, Dr. Barry M. Brenner, Moderator. (Diabetes Control and Complications Trial).
- 1995: Plenary lectures at the Golden Jubilee meetings of Association of physicians of India, Madras, India, Jan. 17-21.
- 1995: Invited speaker at the Diabetes Symposium at the Diabetes Institute, Cairo, Egypt, Sept. 22. (“Preventing Complications of Diabetes”).
- 1995: Invited speaker at the Endocrine Society’s Clinical Endocrinology Update: 1995, San Diego, California, Oct. 22-25 (Clinical Case Discussions on “Diabetic Nephropathy and Renal Preservation”).
- 1996: Visiting Professor, Department of Medicine, Veterans Affairs Medical Center, George Washington University, Washington, D.C. (grand rounds and case discussions). Feb 5.
- 1996: Invited speaker at Leadership Forum “96 on Type II Diabetes at the National Press Club, Washington, D.C., July 19. Carl E. Mogensen, M.D., Chairman. (Clinical implications of the D.C.C.T.)
- 1996: Keynote speaker at the National Nurse Practitioner Conference. Annual Scientific and Clinical Sessions. “Managing Non-insulin Dependent Diabetes Mellitus: The new therapeutic spectrum”. Arlington, Virginia. Oct. 25.
- 1997: Invited speaker at Joslin Education Program in Japan, a symposium organized by R. Kawamori, M.D., Dept of Medicine, School of Medicine, Juntendo University, Tokyo, Japan. Jan 12 (Complications of Diabetes: The Challenge of Prevention)
- 1997: Multiple lectures and case-discussions at Diabetes Education Course, organized by Harvard Medical International, Joslin Diabetes Center, and Sociedade Brasileira de Diabetes. Fortaleza (April 7), Recife (April 9), Salvador (April 11), Brazil.
- 1997: Moderator, Amaryl consultants’ meeting. Hoechst Marion Roussel Pharmaceuticals; Washington, D.C. June 5, 6 (Insulin Resistance syndrome and type II diabetes).
- 1997: Invited speaker at X Congreso Nacional de la Sociedad Espanola de Arteriosclerosis, Gran Canaria, Spain, Sept 24 (Diabetes, Dyslipidemia and Atherosclerosis).
- 1998: Visiting progress at various medical centers in Indonesia (Bandung, Syrabaya, and Jakarta, April 22 thru 25). Keynote speaker on “New Treatment Strategies in type 2 Diabetes”, sponsored by Indonesia Diabetes Association.
- 1998: Endocrine grand rounds at Yale-New Haven Hospital, New Haven, CT. June 5 (issues regarding Diabetes and Atherosclerosis)

Ganda, Om P.

- 1998: Invited speaker of Drew Diabetes Symposium, CR Drew University of Medicine and Science, Los Angeles, CA Nov. 7 (The Role of Oral Agents and Insulin Sensitizers in the Management of Diabetes).
- 1998: ACCE Clinical Symposium, Bethesda, MD. Nov. 14-15. Invited Speaker (Newer Insights Into the Mangement of Diabetes).
- 1999: Invited Speaker, Korean Diabetes Seminar, Je-Ju Island, Korea, April 17 (Therapeutic Trials in the Treatment of Diabetes: From Joslin wisdom to the current issues for the clinician).
- 1999: Invited Speaker at the 10<sup>th</sup> congress of the Asian Federation of Endocrine Societies (AFES); Pre-congress Diabetes Symposium, Bangkok, Thailand. Dec 1: (Type 2 Diabetes Treatment in the next millenium).
- 2000: Invited Speaker, various medical conferences in Japan (Tokyo, Kyoto and Takamatsu, April 1 through 6). "Current trends in the treatment of type 2 diabetes."
- 2001: Visiting Professor, Vanderbilt University Medical Center-Division of Diabetes, Endocrinology, and Metabolism; Nashville, TN. April 23-24.
- 2001: Grand rounds, University of Virginia –Division of Endocrinology and Metabolism, Charlottesville, VA Oct 2.
- 2002: Medical Grand Rounds, St Lukes Hospital at University of Missouri , Kansas City, KS. July 19
- 2002: Invited Speaker at the 2<sup>nd</sup> Associazione Medici Endocrinologi- Italian Association of Clinical Endocrinologists, Clinical Symposium on Hyperlipidemia. Reggio Emilia, Italy. Nov 8-10
- 2003: Invited Speaker and Moderator at Diabetes and Lipid Management Symposia and Workshops at the 12<sup>th</sup> Annual Meetings of the Ameican Association of Clinical Endocrinology, San Diego, CA. May 15-17
- 2003: The M. Viswanathan Oration at the 31<sup>st</sup> Annual conference of the Research Society for the Study of Diabetes ( RSSDI) in India; Jaipur, India. Oct 10-12
- 2004: Invited speaker at the Annual Southeast Asian Diabetes Update; Singapore, Feb 20-21
- 2005: Invited speaker, Diabetes National Symposium sponsored by the Jeddah Diabetes Club; Jeddah, Saudi Arabia. March 3-5

## ORIGINAL REPORTS

1. Ganda OP. Studies in peripheral tissue metabolism of glucose and free fatty acids (forearm preparation) in various clinical types of Indian diabetics. *Ind J Med Res.* 1971; 59:1641-1652.
2. Ganda OP, Mangalik A. Delayed toxic effect of busulfan on the marrow. *J Assoc Physicians Ind.* 1973; 21:511-516.
3. Ganda OP, Caplan HI. Rheumatoid disease without joint involvement. *JAMA* 1974; 228:338-339.
4. Ganda OP, Kahn CB, Soeldner JS, Gleason RE. Dynamics of tolbutamide, glucose and insulin interrelations following varying doses of intravenous tolbutamide in normal subjects. *Diabetes* 1975; 24:354-361.
5. Rossini AA, Aoki TT, Ganda OP, Soeldner JS, Cahill GF, Jr. Alanine-induced amino acid interrelationships. *Metabolism* 1975; 24:1185-1192.
6. Ganda OP, Ruderman NB. Muscle nitrogen metabolism in chronic hepatic insufficiency. *Metabolism* 1976; 25:427-435.
7. Ganda OP, Aoki TT, Soeldner JS, Morrison RS, Cahill GF, Jr. Hormone-fuel concentrations in anephric subjects: Effect of hemodialysis (with special reference to amino acids). *J Clin Invest.* 1976; 57:1403-1411.
8. Ganda OP, Rossini AA, Like AA. Studies on streptozotocin diabetes. *Diabetes* 1976; 25:595-603.
9. Ganda OP., Weir GC, Soeldner JS, Legg MA, Chick WL, Patel YC, Ebeid AM, Gabbay KH, Reichlin S. "Somatostatinoma": A somatostatin-containing tumor of the endocrine pancreas. *N Engl J Med.* 1977; 296:963-967.
10. Ganda OP, Soeldner JS, Gleason RE, Smith TM, Kilo C, Williamson JR. Monozygotic triplets with discordance for diabetes mellitus and diabetic microangiopathy. *Diabetes* 1977;26:469-479.
11. Weglicki WB, Ganda OP, Soeldner JS, Murawski BJ, Cohn LH, Couch NP. Portacaval diversion for severe hypercholesterolemia: Report of a case with measurements of glucose tolerance, insulin and glucagon. *Arch Surg.* 1977; 112:634-636.
12. Ganda OP, Soeldner JS. "Somatostatinoma": Follow-up studies. *N Engl J Med.* 1977; 297:1352-1353.
13. Ganda OP, Sawin CT, Iber F, Glennon JR, Mitchell ML. Transient suppression of growth hormone secretion after chronic ethanol intake. *Alcoholism: Clin and Exp Res.* 1978; 2:297-299.

14. Ganda OP, Day JL, Soeldner JS, Connon JJ, Gleason RE. Reproducibility and comparative analysis of repeated intravenous and oral glucose tolerance tests. *Diabetes* 1978; 27:715-725.
15. Sawin CT, Hershman JM, Fernandez-Garcia R, Ghazvinian S, Ganda OP, Azukizawa M. A comparison of thyroxine and desiccated thyroid in patients with primary hypothyroidism. *Metabolism* 1978; 27:1518-1525.
16. Day JL, Johansen K, Ganda OP, Soeldner JS, Gleason RE, Midgley W. Factors governing insulin and glucagon responses during normal meals. *Clin Endocr.* 1978; 9:443-454.
17. Ruderman NB, Ganda OP, Johansen K. The effect of physical training on glucose tolerance and plasma lipids in maturity-onset diabetes. *Diabetes* 1979; 28 (suppl 1):89-92.
18. Ganda OP, Soeldner JS, Gleason RE, Cleator IGM, Reynolds C. Metabolic effects of glucose, mannose, galactose, and fructose in man. *J Clin Endocrinol Metab.* 1979; 49:616-622.
19. Rhie FH, Ganda OP, Bern MM, Soeldner JS, Gerson B, Azizi F. Insulin resistance and monoclonal gammopathy. *Metabolism* 1981; 30:41-45.
20. Christlieb AR, Warram JH, Krolewski AS, Busick EJ, Ganda OP, Asmal AC, Soeldner JR, Bradley RF. Hypertension - The major risk factor in juvenile-onset insulin dependent diabetics. *Diabetes* 1981; 30 (suppl 2):90-96.
21. Srikanta S, Ganda OP, Eisenbarth GS, Soeldner JS. Islet cell antibody and beta cell function in monozygotic triplets and a twin with 8 and 36 years of discordance for type I diabetes mellitus. *N Engl J Med.* 1983; 308:322-325.
22. Blanc MH, Ganda OP, Gleason RE, Soeldner JS. Improvement of lipid status in diabetic boys. The 1971 and 1979 Joslin Camp lipid levels. *Diabetes Care* 1983; 6:64-66.
23. Ganda OP, Williamson JR, Soeldner JS, Gleason RE, Kilo C, Kaldany A, Miller JP, Garovoy MR, Carpenter CB. Muscle capillary basement membrane width and its relationship to diabetes mellitus in monozygotic twins. *Diabetes* 1983; 32:549-556.
24. Vlachokosta FV, Asmal AC, Ganda OP, Aoki TT. The effect of strict control with the artificial B-cell on plasma lipid levels in insulin dependent diabetes. *Diabetes Care* 1983; 6:351-355.
25. Srikanta S, Ganda OP, Jackson RA, Gleason RE, Kaldany A, Garovoy MR, Milford EL, Carpenter CB, Soeldner JS, Eisenbarth GS. Type I diabetes mellitus in monozygotic twins: chronic progressive beta cell dysfunction. *Ann Intern Med.* 1983; 99:320-326.

26. Patel YC, Ganda OP, Benoit R. Pancreatic somatostatinoma: abundance of somatostatin-28-(1-12)-like immunoreactivity in tumor and plasma. *J Clin Endocr Metab.* 1983; 57:1048-1053.
27. Ganda OP, Srikanta S, Brink SJ, Morris MA, Gleason RE, Soeldner JS, Eisenbarth GS. Selective B-cell insensitivity to intravenous glucose in "early" type I diabetes mellitus. *Diabetes* 1984; 33:516-521.
28. Srikanta S, Ganda OP, Gleason RE, Jackson RA, Soeldner JS, Eisenbarth GS. Pre-type I diabetes: Linear loss of beta cell response to intravenous glucose. *Diabetes* 1984; 33:717-720.
29. Srikanta S, Ganda OP, Jackson RA, Brink SJ, Fleischnick E, Yunis E, Alper C, Soeldner JS, Eisenbarth GS. Pre-type I diabetes: Common endocrinologic course despite immunologic and immunogenetic heterogeneity. *Diabetologia* 1984; 27: 146-148.
30. Ganda OP, Soeldner JS, Gleason RE. Alterations in plasma lipids in the presence of mild glucose intolerance in the offspring of two type II diabetic parents. *Diabetes Care* 1985; 8:254-260.
31. Srikanta S, Ganda OP, Rabizadeh A, Soeldner JS, Eisenbarth GS. First-degree relatives of patients with type I diabetes: Islet-cell antibodies and abnormal insulin secretion. *N Engl J Med* 1985; 313:461-464.
32. Soeldner JS, Tuttleman M, Srikanta S, Ganda OP, Eisenbarth GS. Insulin-dependent diabetes mellitus and autoimmunity: Islet-cell antibodies, insulin autoantibodies and B-cell failure. *N Engl J Med* 1985; 313:893-894.
33. Eisenbarth GS, Fleischnick E, Ganda OP, Srikanta S, Jackson RA, Brink SJ, Soeldner JS, Yunis E, Alper C. Progressive autoimmune B-cell insufficiency: occurrence in the absence of high risk HLA alleles DR3, DR4. *Diabetes Care* 1985; 8:477-480.
34. Battinelli T, Gleason RE, Ganda OP, Cunningham LE. Height-weight indices and blood lipid levels in normal controls and offspring of conjugal diabetics. *Hum Biol* 1986; 58:601-614.
35. Eisenbarth GS, Srikanta S, Jackson RA, Ganda OP, Soeldner JS. Restoration of first-phase insulin secretion by daily prednisone in two islet cell antibody-positive nondiabetic individuals. *Transp. Proc.* 1986; 18:805-808.
36. Kaye WA, Adri MNS, Soeldner JS, Rabinowe SL, Kaldany A, Kahn CR, Bistran B, Srikanta S, Ganda OP, Eisenbarth GS. Acquired defect in interleukin-2 production in patients with type I diabetes. *N Engl J Med.* 1986; 315:920-924.
37. Ganda OP, Srikanta S, Gleason RE, Soeldner JS, Eisenbarth GS. Diminished A-cell secretion in the early phase of type I diabetes mellitus. *Metabolism* 1986; 35:1074-1077.

38. Lokich JJ, Ganda OP, O'Hara C, Warren KW, Moertel CG, Klee G. alpha-fetoprotein associated with islet-cell tumors. *Amer J Clin Onc* 1987; 10:133-135.
39. Ganda OP. Markedly increased erythrocytes sedimentation rate, hyperfibrinogenemia, and peripheral vascular disease in diabetic patients: An association with clinical implications. *Am J Med* 1988; 85:584-585.
40. Brown FM, Vinik AI, Ganda OP, Adri MNS, Rabinowe SL. Different effects of duration on prevalence of anti-adrenal medullary and pancreatic islet-cell antibodies in Type I diabetes mellitus. *Horm Metabol Res* 1989; 21:434-437.
41. Ganda OP, Arkin CF. Hyperfibrinogenemia: An important risk factor for vascular complications in diabetes. *Diabetes Care* 1992; 15:1245-1250.
42. Warram, JH, Laffel, LMB; Ganda OP, Christlieb AR. Coronary artery disease is the major determinant of excess mortality in patients with insulin-dependent diabetes and persistent proteinuria. *J Am Soc Nephrol* 1992; 3 (supple 4):S104-S110.
43. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Eng J Med* 1993; 329:977-986.
44. The Diabetes Control and Complications Trial Research Group (member of the writing team). Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. *Am J Cardiol* 1995; 75:894-903.
45. Raskin P, Ganda OP, Schwartz S, Willard D, Rosenstock J, Lodewick PA, Cressman MD, Phillipson B, Weiner B, McGovern ME, Norton JM, Cucinotta GG, Behounek BD. Efficacy and safety of pravastatin in the treatment of patients with Type I or Type II diabetes mellitus and hypercholesterolemia. 1995; 99:362-369.
46. Ratner RE, Hirsch IB, Neifing JL, Gary SK, Mecca TE, Wilson CA for the U.S. Study Group of Insulin Glargine in type 1 diabetes. *Diabetes Care* 2000; 23:639-643.
47. The Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. *N Engl J Med* 2000; 342: 381-389
48. Rosenstock J, Schwartz SL, Clark CM, Park GD, Donley DW, Edwards MB, et al. Basal insulin therapy in type 2 diabetes. 28-weeks comparison of insulin glargine (HOE 901) and NPH insulin. *Diabetes Care* 2001; 24: 631-636.
49. Diabetes Prevention Program Research Group. Reduction in the incidence of Type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med* 2002; 346: 393-403.
50. Grundy SM, Vega GL, McGovern ME, Tulloch BR, Kendall DM, Fitz-Patrick D, Ganda OP et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes. *Arch Intern Med* 2002; 162: 1568-1576

## REVIEWS

1. Ganda OP, Marble A. Report of workgroup on diabetic ketoacidosis or coma. Report of the National Commission on Diabetes, Vol III, Part 2. Scope and impact of diabetes. DHEW Publication #76-1022. 1977;88-97.
2. Ganda OP, Soeldner JS. Recent progress in the etio-pathogenesis of diabetes mellitus. J All India Inst Med Sciences. New Delhi, India. 1976; 2:14-31.
3. Ganda OP. Marathon racing and myocardial infarction (comments). Ann Intern Med. 1976; 85:389-390.
4. Ganda OP, Soeldner JS. Genetic, Acquired and related factors in the etiology of diabetes mellitus. Arch Intern Med. 1977; 137:461-469.
5. Ganda OP, Soeldner JS. Twins and diabetes. Mother-of-Twins-Notebook. 1978; 18 (No. 3):7-8.
6. Ganda OP. What you should know about fats. Joslin Newsletter. 1979; 8:9-11.
7. Ganda OP. Cholesterol, coronaries, clofibrate and death. (Letter to the Editor) N Engl J Med. 1979; 300:497-498.
8. Ganda OP. Identical twins - their importance to diabetes research. Joslin Research Bulletin. 1980; 3:1-8.
9. Ganda OP. Pathogenesis of macrovascular disease in the human diabetic. Diabetes. 1980; 29:931-942.
10. Ganda OP. New, Purer insulins. Joslin Newsletter. 1980; 9 (No. 2):5.
11. Ganda OP, Soeldner JS. Capillary basement membrane thickness in monozygotic twins. (Letter to the Editor) Lancet 1980; 2:650.
12. Ganda OP. Glucagonoma and diabetic ketoacidosis? (Letter to the Editor) Arch Intern Med. 1980; 140:1397.
13. Ganda OP. Unsnarling the insulin confusion. Joslin Research Bulletin 1981; 4:9-12.
14. Ganda OP. The role of gastrointestinal and neuronal peptides in the pathophysiology of diabetes mellitus. Diabetes Care. 1981; 4:435-442.
15. Ganda OP. Morbidity and mortality from diabetes mellitus – a look at preventable aspects (editorial). Am J Public Health 1983; 73:1156-1158.
16. Ganda OP. Pentamidine and hypoglycemia (Letter to the Editor). Ann Intern Med. 1984; 100:464.

17. Kahn CR, Crettaz M, Grigorescu F, Takayama S, Ganda OP, Flier JS. The role of insulin receptor kinase activity in insulin action: implications from insulin resistant states. In; Labrie F, Proulx L, eds. *Endocrinology 1984; Excerpta Medica, International Congress Series 655*. Elsevier Science Publishers B.V. pp. 249-256.
18. Ganda OP. Challenges in Diabetes Care: Where are we now? *Cont. Education for the Family Physician*. 1985; 20:305-307.
19. Ganda OP. Book Review. *Diabetes Mellitus: Management and Complications (Contemporary Issues in Endocrinology and Metabolism. Vol 1)*. Olefsky JM, Sherwin RS (Eds). Churchill and Livingston, NY 1985. *N Engl J Med* 1985; 313:963.
20. Ganda OP. Book Review. *Brittle Diabetes*. Pickup JC (Ed). Blackwell Scientific, Oxford 1985. *N Engl J Med* 1986; 314:656.
21. Brink SJ, Fleischnik E, Srikanta S, Jackson, RA, Ganda OP, Yunis E, Alper C, Soeldner JS, Eisenbarth GS. Pre-type I diabetes mellitus detected in a screening program. *Pediatr Adolesc Endocr*. 1986; 15:54-60.
22. Ganda, OP. Management of Diabetes in a patient with concurrent malignancy. *Primary Care and Cancer*. 1990; 10:24-36.
23. Ganda, OP. Microalbuminuria: Measurements, determinants and accompaniments (editorial). *Diabetes Res and Clin Practice*. 1991; 11:137-140.
24. Ganda, OP. Book Review. *Treatment of diabetic neuropathy. A new approach*. Horrobin, DF (Ed), Churchill Livingstone, New York 1992. *The Endocrinologist*. 1993; 3:299-300.
25. Ganda, OP, Simonson, DC. Growth hormone, acromegaly, and diabetes. *Diabetes Reviews*. 1993; 1:286-300.
26. Ganda, OP, Simonson, DC. Controlling lipids and blood pressure. In *diabetes, new findings and better outcomes*. GC Weir, K Singer (eds). *Patient Care* 15:61-72, 1995.
27. Ganda, OP. Book Review. *Diabetes*. Cowett, RM (Ed.) Lippincott-Raven Publishers 1995. *The Endocrinologist*. 6:153, 1996.
28. Ganda, OP. Management of diabetic patients with “abnormal” blood pressure: selection of antihypertensive agents. *Endocrine Practice* 2:276-279, 1996.
29. Garcia, E, Ganda, OP. Cuidados perioperatorios de pacientes con diabetes mellitus. In *Endocrinología. Controversias Medico-Quirúrgicas*. Herrera, MF, Garber, IL, Rodrigo, Jr, Fernandez, MC (Eds). McGraw Hill Interamericana. Mexico 1996:345-351.
30. Ganda, OP. Improved glycemic control reduces microvascular complications in type 2 diabetes mellitus (commentary) *Evidenced-Based Medicine* 1998; 3:147.

31. Ganda, OP. Factors in selecting treatment in type 2 diabetes. Interview. Digest. Nov. 1999; pg 1-5.
32. Ganda, OP, Golden SH, O'Brien, T (consultants). Strategies to limit heart disease in Diabetes. Patient Care 1999; 33 (no.19):37-49.
33. Ganda, OP. A 2-hours oral glucose tolerance test result  $\geq 11.1$ mmol/L predicted all-cause mortality better than a fasting glucose level  $\geq 7.0$ mmol/L (commentary) ACP Journal Club 2000; 132:70.
34. Ganda, OP. Lipoatrophy, Lipodystrophy, and Insulin Resistance (editorial) Ann Intern Med 2000; 133:304-306.
35. Ganda, OP. Interventions that lower cholesterol concentrations or blood pressure in diabetic patients prevent cardiovascular disease ( Commentary). Evidence- Based Medicine 2002; 7: 107
36. Insulin Resistance Syndrome Conference Faculty. American College of Endocrinology Position Statement on the Insulin Resistance Syndrome . Endocrine Practice. 2003; 9: 240-252
37. Ganda, OP. Insulin Resistance Syndrome: Implications for the Asian American population. Endocrine Practice 2003; 9(supp 2) : 31-34
38. Ganda, OP. The role of lipid management in Diabetes. Cardiology Clinics 2005; 23: 153-164

1. Ganda OP. Studies on peripheral tissue metabolism of glucose and free fatty acids (forearm preparation) in various clinical types of Indian diabetics. Thesis; All India Institute of Medical Sciences. New Delhi, India, 1970.
2. Ganda OP, Soeldner JS. Relationship between insulin secreting islet cell tumors and diabetes mellitus. In: Podolsky S, Viswanathan M, eds. Secondary diabetes: the spectrum of the diabetic syndromes. New York, Raven Press, 1980:297-306.
3. Ganda OP. Lipid disorders and diabetes. In: Kozak GP, ed. Clinical Diabetes Mellitus. Philadelphia, WB Saunders, 1982:317-326.
4. Ganda OP, Soeldner JS. Diabetes secondary to endocrinopathies. In: Ellenberg M, Rifkin H, eds. Diabetes mellitus: theory and practice. Third ed. New York, Medical Examination Publishing Co., Inc. 1983:1005-1020.
5. Ganda OP. Pathogenesis of accelerated atherosclerosis in diabetes. In: Kozak GP et al (eds). Management of Diabetic Foot Problems. Philadelphia, WB Saunders, 1984:17-26.
6. Ganda OP. Hormones and related factors affecting the secretion and actions of insulin. In: Marble A, Krall LP, Bradley RF, Christlieb AR, Soeldner JS. eds. Joslin's Diabetes Mellitus. 12<sup>th</sup> ed. Lea and Febiger, Philadelphia; 1985:158-184.
7. Ganda OP. Pathogenesis of macrovascular disease (including the influence of lipids). In: Marble A, Krall L, Bradley RF, Christlieb AR, Soeldner JS, eds. Joslin's Diabetes Mellitus. 12<sup>th</sup> ed. Lea and Febiger, Philadelphia; 1985:217-250.
8. Ganda OP. Gastrointestinal manifestations of endocrine tumors. In: Hare JW (Ed). Signs and Symptoms in Endocrine and Metabolic disorders. J.B. Lippincott Company, Philadelphia; 1986:261-272.
9. Ganda OP. Disorders of lipid metabolism. In: Lavin, N. (Ed) Manual of Endocrinology and Metabolism. Little, Brown and Co., Boston; 1986:473-486.
10. Ganda OP. Diet and exercise in Diabetes Mellitus. In: Becker KL, et.al. (Eds.) Principles and Practice of Endocrinology and Metabolism. JB Lippincott Company, Philadelphia; 1990:1096-1098.
11. Ganda OP, Weir GC. Oral Hypoglycemic agents. In: Becker KL, et.al. (Eds.) Principles and Practice of Endocrinology and Metabolism. JB Lippincott Company, Philadelphia; 1990:1096-1098.
12. Ganda OP. Diabetes secondary to endocrinopathies. In: Rifkin H, Porte D (eds). Ellenberg and Rifkin's Diabetes Mellitus, Theory and Practice. Fourth ed. Elsevier Science Publishing Co, Inc., N.Y. 1990:911-921.
13. Dayal, Y, Ganda, OP. Somatostatin - producing tumors and the somatostatinoma syndrome. In: Dayal, Y (ed). Endocrine pathology of the gut and pancreas. CRC press, Inc., Boca Raton 1991:241-277.

14. Ganda, OP, Arkin, CF. Hyperfibrinogenemia: A major determinant of Vascular complications in diabetes. In Ernst, E, Koenig, W, Lowe, G.D.O., and Meade, TW (Eds). Fibrinogen: A “new” cardiovascular risk factor. Blackwell-MZV; Vienna 1992:254-258.
15. Ganda, OP. Disorders of lipid metabolism. In, Lavin, M (ed). Manual of Endocrinology and Metabolism. 2<sup>nd</sup> edition. Little Brown and Co., Boston 1994:477-491.
16. Rosenzweig, JL, Beaser, R, Crowell, S, Friedlander, E, Ganda, OP, Halford, B, Jacobson, A, Rand, LI, Stewart, C, Wolfsdorf, JI. Findings of the Diabetes Control and Complications Trial. In Kahn, CR, and Weir, GC (Eds). Joslin’s Diabetes Mellitus, 13<sup>th</sup> edition. Lea and Febiger, Philadelphia 1994:1022-1027.
17. Ganda, OP. Secondary forms of diabetes. In, Kahn, CR and Weir, GC (Eds). Joslin’s Diabetes Mellitus. 13<sup>th</sup> edition. Lea and Febiger, Philadelphia 1994:300-316.
18. Ganda, OP. Diet and Exercise in Diabetes Mellitus. In Becker KL et al (Eds). Principles and Practice of Endocrinology and Metabolism. 2<sup>nd</sup> edition. JB Lippincott Co., Philadelphia 1995:1231-1235.
19. Ganda OP. Incidence and prevalence of other types of diabetes. In Harris, MI (ed). Diabetes in America, 2<sup>nd</sup> edition. NIH, Publication 95-1468, 1995; 69-84.
20. Ganda, OP. Exercise in special patient groups: Patients on various drug therapies. N Ruderman, JT Devlin (Eds). In the Health Professional’s Guide to Diabetes and Exercise. American Diabetes Association, Alexandria, VA 1995; 233-240.
21. Ganda, OP. Diabetes Secondary to Endocrinopathies. In Ellenberg and Rifkin’s Diabetes Mellitus. 5<sup>th</sup> ed. D. Porte Jr. and R. Sherwin (Eds). Appleton and Lange. Stamford, CT 1997; 595-608.
22. Ganda OP. Diet and Exercise in Diabetes Mellitus. In Becker, KL et al. (Eds). Principles and Practice of Endocrinology and Metabolism. 3<sup>rd</sup> ed. J.B. Lippincott Co. Philadelphia 2001; 1340-1344.
23. Ganda, OP. Exercise in Special Patient Groups : Patients on various drug therapies. In Handbook of Exercise in Diabetes. N. Ruderman, JT Devlin, SH Schneider (Eds). American Diabetes Association , Alexandria, VA 2001; 587-599
24. Ganda, OP, Bachman, ES Diabetes Secondary to Endocrinopathies. In Ellenberg and Rifkin’s Diabetes Mellitus. 6<sup>th</sup> ed. D. Porte Jr., R. Sherwin, and A. Baron (Eds). McGraw-Hill , New York. 2003; 425-435
25. Ganda, OP. Secondary forms of diabetes. In, Kahn, CR et al (Eds). Joslin’s Diabetes Mellitus 14<sup>th</sup> edition. Lea and Febiger, Philadelphia 2005 (In Press)